Nxera Pharma Assigns Cenerimod Rights to Viatris in APAC Deal

In a strategic move to expand access to innovative autoimmune therapies, Nxera Pharma has assigned its rights to develop and commercialize cenerimod in Japan, South Korea, and select Asia-Pacific countries to Viatris Inc. This deal, originally secured through Nxera’s acquisition of Idorsia Pharmaceuticals Japan and Korea, will grant Nxera an upfront payment of $10 million, with potential milestone payments and royalties upon regulatory approval. Cenerimod, an oral sphingosine-1-phosphate receptor 1 (S1P1) modulator developed by Idorsia, is currently undergoing Phase 3 trials as a first-in-class treatment for systemic lupus erythematosus (SLE).

With this agreement, Viatris now holds the exclusive global rights to cenerimod, further strengthening its immunology pipeline. The collaboration reflects a growing commitment to addressing autoimmune diseases, offering hope for patients with limited treatment options. By securing this partnership, Nxera ensures that its innovative research translates into real-world impact while benefiting from Viatris’ global expertise in commercialization.